Condition: Alzheimer Disease · Sponsor: Eli Lilly and Company
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.
This description comes directly from the study's public registry record.
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Rehabilitation & Neurological Services | Huntsville, Alabama, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06566170